Detalhe da pesquisa
1.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
BMC Cancer
; 23(1): 908, 2023 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752423
2.
Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8302-8314, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976464
3.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Int J Mol Sci
; 23(7)2022 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35408919
4.
Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells.
Int J Mol Sci
; 23(2)2022 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35055018
5.
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Int J Mol Sci
; 22(8)2021 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921561
6.
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.
Int J Mol Sci
; 21(12)2020 Jun 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32575899
7.
Veliparib: a new therapeutic option in ovarian cancer?
Future Oncol
; 15(17): 1975-1987, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31074636
8.
Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer.
Int J Mol Sci
; 20(9)2019 May 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31083638
9.
Correction: Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8319, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36131118
10.
ASO Visual Abstract: Clinical and Histopathologic Predictors Signaling Recurrence of Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Ann Surg Oncol
; 29(13): 8317-8318, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36109407
11.
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Tumori
; 109(5): 490-495, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36609207
12.
Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1247291, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37781174
13.
MITO39: Efficacy and Tolerability of Pegylated Liposomal Doxorubicin (PLD)-Trabectedin in the Treatment of Relapsed Ovarian Cancer after Maintenance Therapy with PARP Inhibitors-A Multicenter Italian Trial in Ovarian Cancer Observational Case-Control Study.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201470
14.
Corrigendum: Management of metastatic endometrial cancer: physicians' choices beyond the first line after approval of checkpoint inhibitors.
Front Oncol
; 13: 1357793, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318323
15.
Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
Cancers (Basel)
; 15(4)2023 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36831376
16.
Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
Cancers (Basel)
; 15(14)2023 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37509300
17.
From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia.
Front Oncol
; 12: 859071, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35493999
18.
Management of Metastatic Endometrial Cancer: Physicians' Choices Beyond the First Line. A MITO Survey.
Front Oncol
; 12: 880008, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35692798
19.
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
Front Oncol
; 11: 689829, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195090
20.
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.
Cells
; 10(12)2021 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34943916